.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Deloitte
Novartis
Harvard Business School
Merck
Teva
Cerilliant
Healthtrust
Fish and Richardson
Citi

Generated: September 19, 2017

DrugPatentWatch Database Preview

METIMYD Drug Profile

« Back to Dashboard

What is the patent landscape for Metimyd, and what generic Metimyd alternatives are available?

Metimyd is a drug marketed by Schering and is included in one NDA.

The generic ingredient in METIMYD is prednisolone acetate; sulfacetamide sodium. There are eighty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.

Summary for Tradename: METIMYD

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list59
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:METIMYD at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
METIMYD
prednisolone acetate; sulfacetamide sodium
OINTMENT;OPHTHALMIC010210-002Sep 9, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
METIMYD
prednisolone acetate; sulfacetamide sodium
SUSPENSION/DROPS;OPHTHALMIC010210-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Queensland Health
Teva
Mallinckrodt
Healthtrust
McKinsey
QuintilesIMS
Cerilliant
Fuji
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot